↓ Skip to main content

Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis

Overview of attention for article published in Cochrane database of systematic reviews, May 2013
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news
2 news outlets
blogs
1 blog
policy
1 policy source
twitter
25 tweeters
facebook
5 Facebook pages
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
105 Dimensions

Readers on

mendeley
6 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis
Published in
Cochrane database of systematic reviews, May 2013
DOI 10.1002/14651858.cd000951.pub2
Pubmed ID
Authors

Beverley Shea, Michael V Swinden, Elizabeth Tanjong Ghogomu, Zulma Ortiz, Wanruchada Katchamart, Tamara Rader, Claire Bombardier, George A Wells, Peter Tugwell

Abstract

Methotrexate (MTX) is a disease modifying antirheumatic drug (DMARD) used as a first line agent for treating rheumatoid arthritis (RA). Pharmacologically, it is classified as an antimetabolite due to its antagonistic effect on folic acid metabolism. Many patients treated with MTX experience mucosal, gastrointestinal, hepatic or haematologic side effects. Supplementation with folic or folinic acid during treatment with MTX may ameliorate these side effects.

Twitter Demographics

The data shown below were collected from the profiles of 25 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 6 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 6 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 1 17%
Student > Ph. D. Student 1 17%
Unknown 4 67%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 1 17%
Medicine and Dentistry 1 17%
Unknown 4 67%

Attention Score in Context

This research output has an Altmetric Attention Score of 50. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 July 2019.
All research outputs
#348,588
of 13,514,645 outputs
Outputs from Cochrane database of systematic reviews
#975
of 10,621 outputs
Outputs of similar age
#4,020
of 151,962 outputs
Outputs of similar age from Cochrane database of systematic reviews
#8
of 144 outputs
Altmetric has tracked 13,514,645 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 10,621 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.0. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 151,962 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 144 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.